AnaptysBio Completes First Tracks Spin-Off, Refocuses on Royalties

The latest announcement is out from AnaptysBio ( (ANAB) ).

On April 20, 2026, AnaptysBio completed the spin-off of First Tracks Biotherapeutics, separating its biotechnology R&D operations from a royalty-focused business that will retain and manage Jemperli and imsidolimab royalty streams and related collaborations with GSK and Vanda. The transaction transferred about $100 million in cash, IP, employees, clinical programs and leases to First Tracks, while AnaptysBio kept royalty-related assets and liabilities, implemented broad mutual indemnities and tax-sharing rules, and put in place a two-year transition services framework.

The separation triggered significant governance and management changes, including the resignations of four directors in April 2026, the move of Chief Medical Officer Paul Lizzul to the same role at First Tracks and a new consulting-based CEO arrangement that keeps Daniel Faga leading AnaptysBio at least through January 15, 2027. AnaptysBio now runs a streamlined, virtual structure aimed at maximizing shareholder returns from its royalty portfolio, while First Tracks assumes full responsibility for advancing rosnilimab, ANB033 and ANB101 and for post-spin employee and benefit obligations.

The spin-off also formalized complex arrangements on asset allocation, shared contracts, IP licensing and access to information designed to minimize operational disruption and clearly allocate risks between the two companies. Both sides agreed to non-solicitation covenants, detailed equity award conversions and ongoing support services so that First Tracks can operate independently while AnaptysBio continues to meet collaboration obligations and maintain its Nasdaq listing under the ANAB ticker.

The most recent analyst rating on (ANAB) stock is a Buy with a $69.00 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.

Spark’s Take on ANAB Stock

According to Spark, TipRanks’ AI Analyst, ANAB is a Neutral.

The score is held back primarily by weak and volatile financial quality (negative gross profit, historical losses, and past leverage volatility) despite a clear 2025 improvement in revenue and cash flow. Technicals are moderately supportive, corporate actions add a positive catalyst, but valuation remains challenging due to negative earnings and no dividend.

To see Spark’s full report on ANAB stock, click here.

More about AnaptysBio

AnaptysBio, Inc., now describing itself as a royalty management company, focuses on managing financial collaborations tied to cancer drug Jemperli with GSK and autoimmune candidate imsidolimab with Vanda Pharmaceuticals. The San Diego-based firm no longer conducts internal biopharma R&D and operates as a virtual company with limited staff, minimal operating expenses and a high projected EBIT margin, while its former drug development assets reside in newly spun-off First Tracks Biotherapeutics.

Average Trading Volume: 525,567

Technical Sentiment Signal: Buy

Current Market Cap: $1.95B

Find detailed analytics on ANAB stock on TipRanks’ Stock Analysis page.